Trade Vertex Pharmaceuticals Incorporated - VRTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 421.59 |
| Open | 424.13 |
| 1-Year Change | -2.46% |
| Day's Range | 423.77 - 429.87 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 421.94 | 3.92 | 0.94% | 418.02 | 427.97 | 418.02 |
| Jan 16, 2025 | 416.68 | -2.76 | -0.66% | 419.44 | 422.31 | 414.48 |
| Jan 15, 2025 | 422.81 | 10.60 | 2.57% | 412.21 | 425.27 | 412.21 |
| Jan 14, 2025 | 410.07 | -0.63 | -0.15% | 410.70 | 414.12 | 405.91 |
| Jan 13, 2025 | 413.32 | 6.37 | 1.57% | 406.95 | 416.34 | 396.20 |
| Jan 10, 2025 | 409.31 | 4.19 | 1.03% | 405.12 | 413.45 | 403.55 |
| Jan 8, 2025 | 411.83 | 1.88 | 0.46% | 409.95 | 412.21 | 406.14 |
| Jan 7, 2025 | 408.37 | 5.90 | 1.47% | 402.47 | 410.49 | 400.78 |
| Jan 6, 2025 | 401.49 | 0.22 | 0.05% | 401.27 | 404.46 | 397.39 |
| Jan 3, 2025 | 406.01 | 1.77 | 0.44% | 404.24 | 411.48 | 404.15 |
| Jan 2, 2025 | 404.37 | 1.46 | 0.36% | 402.91 | 408.74 | 400.66 |
| Dec 31, 2024 | 402.61 | 5.52 | 1.39% | 397.09 | 404.43 | 397.09 |
| Dec 30, 2024 | 398.35 | -6.09 | -1.51% | 404.44 | 407.00 | 397.58 |
| Dec 27, 2024 | 407.68 | 4.35 | 1.08% | 403.33 | 410.60 | 402.12 |
| Dec 26, 2024 | 410.37 | 4.58 | 1.13% | 405.79 | 411.10 | 403.33 |
| Dec 24, 2024 | 407.30 | 7.46 | 1.87% | 399.84 | 410.63 | 398.15 |
| Dec 23, 2024 | 404.96 | 18.33 | 4.74% | 386.63 | 405.77 | 386.63 |
| Dec 20, 2024 | 395.95 | 5.92 | 1.52% | 390.03 | 400.77 | 384.55 |
| Dec 19, 2024 | 396.29 | 8.81 | 2.27% | 387.48 | 403.95 | 376.15 |
| Dec 18, 2024 | 446.10 | -17.46 | -3.77% | 463.56 | 470.09 | 444.95 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Vertex Company profile
Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops and commercialises innovative medicines.
Founded in 1989, Vertex is headquartered in Boston, Massachusetts, with international headquarters in London, UK. The company focuses on health conditions like cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, duchenne muscular dystrophy and type 1 diabetes.
The company designed and developed Symdeko/Symkevi, Orkambi and Kalydeco for cystic fibrosis, and Trikafta for patients aged six years or older with at least one F508del mutation. There are several products in the pipeline, such as VX-864 for the treatment of AAT deficiency, VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, VX- 880 for Type 1 Diabetes and VX-548, a NaV1.8 inhibitor for treatments of neuropathic and musculoskeletal pain.
Vertex sells its products to specialty pharmacies and distributors, hospitals and clinics. It has collaborations and partnership deals with CRISPR Therapeutics AG, Moderna, Arbor Biotechnologies and several other pharma companies that support the commercialisation of drugs.
The company went public in 1991. Vertex Pharmaceuticals Incorporated stock trades on the Nasdaq under the ticker symbol VRTX.
You can follow the VRTX share value and price movement live through stock charts at Capital.com.
| Industry: | Bio Therapeutic Drugs |
50 Northern Avenue
BOSTON
MASSACHUSETTS 02210
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com